FRα is overexpressed in the majority of high-grade serous ovarian carcinomas and serves not only as a diagnostic and prognostic biomarker but also as a therapeutic target for antibody–drug conjugates, such as mirvetuximab soravtansine [6,7,8,9,10,11,12,13]. This evidence concerns the gene FOLR1 and ovarian serous carcinoma.